Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial

Overview of attention for article published in Arthritis & Rheumatology, June 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#29 of 3,088)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 42 news outlets
blogs: 3 blogs

twitter: 12 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 29 Mendeley

Summary News Blogs X Dimensions citations

So far, Altmetric has seen 3 posts from 3 blogs.

Brepocitinib Beneficial for Moderate-to-Severe Psoriatic Arthritis

Physician's Weekly, 19 May 2023

THURSDAY, May 18, 2023 (HealthDay News) — For patients with moderately to severely active psoriatic arthritis, the tyrosine…

Clinical trial shows efficacy and safety of brepocitinib for treating adults with psoriatic arthritis

news-medical.net, 17 May 2023

Brepocitinib is an oral drug that inhibits certain enzymes involved in inflammation-;called tyrosine kinase 2 and Janus kinase 1…

Does brepocitinib benefit patients with psoriatic arthritis?

Health Medicine Network, 17 May 2023

More information: Efficacy and Safety of Tyrosine Kinase 2/Janus Kinase 1 Inhibitor Brepocitinib for Active Psoriatic Arthritis…

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.